The Myriad Case and "Gene" Patents: Much Ado about Nothing?

by McDonnell Boehnen Hulbert & Berghoff LLP

LargecoverThe biggest concern of the biotechnology industry caused by the impending Supreme Court decision in the AMP v. Myriad Genetics case is the threat to existing patents having claims to isolated human DNA (and the DNA from other species) that a negative decision from the Court could raise.  Patent protection has been an important component of the success of companies from Genentech to Myriad and many others, and the prospect of a categorical ban (ironic, in view of the Court's anathema for "bright line" rules promulgated by the Federal Circuit) threatens the success paradigm developed over the past 30 years.  While the extent of whatever deleterious effects on the progress of the biotechnology arts that the Court may impose by its Myriad decision is still to come, an article in the May edition of Nature Biotechnology suggests that those effects may be ameliorated by the anachronistic aspects of the Myriad case:  in many ways this argument is coming 30 years to late, and the future of biotechnology is less dependent on so-called "gene patents" than at any other time in the history of the biotechnology industry.

The article, "Not quite a myriad of gene patents," by Gregory Graff, Devon Phillips, Zhen Lei, Sooyoung Oh, Carol Nottenburg, and Philip Pardey, provides a survey of existing patents claiming isolated human DNA.  After providing a brief history of the Myriad case, the paper provides data on the number of U.S. patents containing different types and extents of isolated human DNA:

• Patents that identify DNA or RNA "anywhere" in the patent document
• Patents that identify DNA or RNA in the claims (providing upper and lower estimates)
• Patents with at least one composition of matter claim directed to isolated DNA or RNA (numbering 15,359 patents according to these authors)

Previously published estimates of the number of such patents claiming human DNA vary widely, with a high of 40,000 from a National Research Council report to a emerging consensus of ~4,000 – 5,000 patents that claims isolated human DNA.  The paper also addresses the philosophical and practical consequences that could arise if the Court narrowly answered the Question Presented in a decision limited to human DNA, in contrast to DNA from other species.

The quantitative aspects of the paper involve an analysis of claim language in claims reciting isolated human DNA, thereby identifying 72,052 U.S. patents that "in some way identify or make reference to nucleotide sequences."  Of these, the authors report that from 30-39% of these patents (21,870 – 28,410 patents) were "likely to contain or refer to nucleotide sequences in at least one of the claims of the patent."  Finally, the paper identifies from this population patents that contain at least one composition of matter claim to an isolated human nucleic acid, which are reported to be 15,359 patents.  (As an interesting aside, there were 82,952 method claims in the 72,052 patents that recited human DNA or RNA.)  Of these 15,359 patents, 5,936 (39%) "primarily involve" isolated human DNA, with the remainder being directed to isolated DNA molecules from other animals (1,056; 7%); plants (1,847; 12%);  microbes (3,228; 21); and synthetic or artificial sequences (3,292; 21%).  (Methodologically, the authors considered claims to artificial or synthetic sequences to be "markedly different" from naturally occurring DNA and omitted these patents from further analysis.)

Looking at the timing of patents granted on isolated DNA, the authors report that the number of patents containing such claims peaked in 1999 and has been declining since 2005 (no doubt due to a combination of the more stringent utility requirements imposed by the U.S. PTO in 2001 and the change from isolating DNA encoding a particular protein and isolating human DNA containing an open reading frame as identified by genome sequencing efforts, predominantly related to the Human Genome Project).  The proportion of patents claiming isolated human DNA peaked in 2000, where 58% of "gene" patents recited human DNA, and by 2010 this percentage had fallen to 19%.

Of the patents containing claims to isolated DNA that could encompass "naturally occurring" molecules, the authors identified 8,703 that remain in force, with 3,535 (41%) of these patents claiming isolated human DNA and less than half of these patents being related to human medicine (an area about which at least Justice Breyer has evinced a particular concern on the possibility of negative effects of patenting on patient care).  The assignee data the authors report are a little surprising, with 65% of the 15,359 patents containing composition of matter claims reciting isolated DNA molecules being owned by private-sector commercial assignees, and only 24% being owned by public-sector (identified as "government, university, nonprofit") assignees (the remainder being owned by some combination of public- and private-sector assignees).  The "Top Twenty-five" assignees (and the number of patents assigned to them) are reported to be:

The authors speculate on the reason for the decline in patents claiming isolated nucleic acids, providing some clear correlations (the crash of the tech bubble at the turn of the century, the Tableavailability on public databases of human genomic DNA sequences and the prior art effect, and the more stringent utility requirements).  The authors also recognized that the 1999-2000 timeframe also marked a change from claims to isolated human DNA molecules per se to claims reciting "complex genetic constructs" (presumably including expression constructs).  The authors also note the trend over the past decade towards claims to molecules comprising artificial or synthetic sequences (from 14% to 40%) rather than "naturally occurring" DNA molecules (from 58% to 19%).  Nevertheless, the 3,535 patents claiming isolated human DNA remain at risk for invalidation to some extent by the Supreme Court's Myriad decision (and, the authors note, the remaining 4,538 patents claiming isolated DNA from other species might also be at risk if the Court rules more broadly).  Consequently:

[A]n overturn by the Supreme Court will affect claims of patents not only on human genetic diagnostics and therapeutics but also on a wide range of other genetic technologies in other industries, particularly in agriculture, based upon our analysis of top assignee portfolios.

The authors attempt to find a silver lining in their analyses, particularly with regard to sequence variants and genetically engineered constructs, which may have a greater likelihood to evince "the hand of man" and to be "markedly different" from naturally occurring DNA.  They perceive a trend towards this type of innovation that a "product of nature" exception from the Court would "accelerate," and more recent events (the PTO's decision to examine one sequence per invention and the Federal Circuit's expansion of obviousness towards isolated DNA in In re Kubin) are not accounted for in the data.  Thus:

The outcome of the Myriad case, regardless, is thus likely to be less profound than either abolitionists or advocates seem to expect.  In the end, any policy effects resulting from the Myriad case may prove to have been largely preempted by a combination of less dramatic changes in examination practices and patent law.

While outside the scope of the data presented in their paper, the authors also neglect to consider the effects of a broad "product of nature" ban by the Court on biotechnology more generally (a concern voiced by Judge Moore in oral argument and her concurring opinions in the Federal Circuit's review of the Myriad decision).  It is possible, as the authors posit, that the negative effects of whatever decision is handed down by the Court will be ameliorated by advances in DNA technology (and the capacity of competent patent draftsmen to adapt claiming strategies to accommodate their clients' needs in view of the Court's proscriptions).  But it is equally likely that the Court will seriously harm the economic incentives for commercializing genetic technology and inhibit disclosure of new correlations between disease and genetic variation, all to the detriment of progress in this industry.  And it is a near certainty that the purported purpose behind the controversy, better access to genetic testing for patients, will not be one of the outcomes of any decision that impairs the ability to commercializing genetic testing.  In the end, the question is not how many patents are at risk from the Court's consideration of the question before it, but rather why do the Justices not realize that now is not the time to wade unnecessarily into these particular philosophical waters.  It is ultimately a political, not a legal, question, and one better suited for consideration by the (expressly) political branches of the government.



Written by:

McDonnell Boehnen Hulbert & Berghoff LLP

McDonnell Boehnen Hulbert & Berghoff LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at:

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.